



Bendamustine (hydrochloride)

Catalog No: tcsc1771

Available Sizes
Size: 100mg
Size: 200mg
Size: 500mg
Specifications
CAS No: 3543-75-7
Formula: C ₁₆ H ₂₂ Cl ₃ N ₃ O ₂
Pathway: Cell Cycle/DNA Damage
Target: DNA Alkylator/Crosslinker
Purity / Grade: >98%
Solubility: DMSO : ≥ 30 mg/mL (76.00 mM)
Alternative Names: SDX-105;EP-3101
Observed Molecular Weight: 394.72





Bendamustine hydrochloride is a **DNA cross-linking** agent that causes DNA breaks, with alkylating and antimetabolite properties.

IC50 & Target: DNA Alkylator/Crosslinker^[1]

In Vitro: Bendamustine hydrochloride is a DNA cross-linking agent that causes DNA breaks, with alkylating and antimetabolite properties. Bendamustine uniquely regulates apoptosis pathways and DNA repair pathways in non-Hodgkin\'s lymphoma cells. Bendamustine (50 μ M) induces p21 (Cip1/Waf1) and NOXA genes, and increases the expression of p53 in SU-DHL-1 cells. Bendamustine (25 μ M) blocks mitotic checkpoints and cuases mitotic catastrophe^[1]. Bendamustine reduces the viability of multiple myeloma (MM) cell lines, such as RPMI-8226 and 8226-LR5 cells, with IC₂₅s of 101.8 and 585.5 μ M after 24 h incubation, and 51.7 and 374.3 μ M after 48 h incubation, respectively. Bendamustine induces a specific caspase-dependent MM cell death and inhibits the spindle-assembly checkpoint^[2].

In Vivo: Bendamustine (25 mg/kg, i.v.) shows potent inhibition on the growth of tumor cells by 91%, 99% and 95% for DoHH-2, Granta 519 and RAMOS models, respectively. Moreover, the antitumor effect of Bendamustine is enhanced by rituximab in DoHH-2 and RAMOS models, but not in Granta 519 model^[3].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!